Experience
Elan Pharmaceuticals, Inc.
Ivax Pharmaceuticals, Inc.
Represented Elan in Hatch-Waxman patent infringement action against Ivax seeking FDA approval to market generic copies of Permax®, ultimately concluded after product sold to another party.
Elan Pharmaceuticals, Inc. v. Ivax Pharmaceuticals, Inc., 2:01-cv-01974, D.N.J., Judge Martini
Valeant Pharmaceuticals Int’l, Inc. v. Mylan Pharmaceuticals, Inc.
Valeant; Salix; Progenics
Dow Pharmaceutical Sciences, Inc. v. Taro Pharmaceuticals U.S.A., Inc.
Dow Pharmaceutical Sciences, Inc.; Valeant
Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc.
Dow Pharmaceutical Sciences, Inc.
Dow Pharmaceutical Sciences, Inc. v. Actavis, Inc.
Dow Pharmaceutical Sciences, Inc.
Medicis Pharmaceutical Corp. v. Apotex, Inc.
Medicis Pharmaceutical Corp.
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.
Elan Pharmaceuticals, Inc.
Medicis Pharmaceutical Corp. v. Taro Pharmaceuticals USA, Inc.
Medicis Pharmaceutical Corp.
Medicis Pharmaceutical Corp. v. Zydus Pharmaceuticals (USA) Inc.
Medicis Pharmaceutical Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.